{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:54:41Z","timestamp":1780592081883,"version":"3.54.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s10194-019-1010-3","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T15:04:22Z","timestamp":1558105462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Optimising migraine treatment: from drug-drug interactions to personalized medicine"],"prefix":"10.1186","volume":"20","author":[{"given":"Leda Marina","family":"Pomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Guglielmetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bertamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Borro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"1010_CR1","volume-title":"World Healt report 2001: mental health: new undersanding, new hope","author":"World Health organization","year":"2001","unstructured":"World Health organization. (2001); World Healt report 2001: mental health: new undersanding, new hope"},{"issue":"6","key":"1010_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10194-005-0252-4","volume":"6","author":"M Leonadri","year":"2005","unstructured":"Leonadri M, Steiner TJ, Sacher AT, Lipton RB (2005) The global burden of migraine: measuring disability in headache disorderswith WHO\u2019s classification of Funtioning, disability and Healt (ICF). J Headache Pain 6(6):429\u2013440","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1010_CR3","first-page":"1","volume":"24","author":"Headache Classification Subcommettee of International Society","year":"2004","unstructured":"Headache Classification Subcommettee of International Society (2004) The international classification of headache disorders: 2nd edn. Cephalalgia 24(Suppl 1):1\u2013160","journal-title":"Cephalalgia"},{"key":"1010_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ncl.2008.11.011","volume":"27","author":"ME Bigal","year":"2009","unstructured":"Bigal ME, Lipton RB (2009) The epidemiology, burden, and comorbidities of migraine. Neurol Clin 27:321\u2013334","journal-title":"Neurol Clin"},{"issue":"6","key":"1010_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1101\/gr.5574907","volume":"17","author":"AA Bhinge","year":"2007","unstructured":"Bhinge AA, Kim J, Euskirchen GM, Snyder M, Iyer VR (2007) Mapping the chromosomal targets of STAT1 by sequence tag analysis of genomic enrichment (STAGE). Genome Res 17(6):910\u2013916","journal-title":"Genome Res"},{"key":"1010_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10194-012-0478-x","volume":"13","author":"C Di Lorenzo","year":"2012","unstructured":"Di Lorenzo C, Grieco GS, Saltorelli FM (2012) Migraine headache: a review of the molecular genetics of common disorder. J Headache Pain 13:571\u2013580","journal-title":"J Headache Pain"},{"key":"1010_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2174\/13892029113149990007","volume":"14","author":"CF Gasparini","year":"2013","unstructured":"Gasparini CF, Sutherland HG, Griffiths LR (2013) Studies on the pathophysiology and genetic basis of migraine. Curr Genomics 14:300\u2013315","journal-title":"Curr Genomics"},{"issue":"1","key":"1010_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10194-011-0399-0","volume":"13","author":"M Schurks","year":"2012","unstructured":"Schurks M (2012) Genetics of migraine in the age of genoma-wide associations studies. J Headache Pain 13(1):1\u20139","journal-title":"J Headache Pain"},{"key":"1010_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuroscience.2016.04.041","volume":"338","author":"Z\u2013 Lichtenwalter k","year":"2016","unstructured":"Lichtenwalter k Z\u2013, Meloto CB, Khoury S, Diatchenko L (2016) Genetic predictions of human chronic pain conditions. Neuroscience 338:36\u201362","journal-title":"Neuroscience"},{"key":"1010_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","volume":"3","author":"HC Diener","year":"2004","unstructured":"Diener HC, Limmorth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475\u2013483","journal-title":"Lancet Neurol"},{"key":"1010_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1046\/j.1526-4610.2002.02209.x","volume":"42","author":"K Kotani","year":"2002","unstructured":"Kotani K, Shimomura T, Shimomura F, Ikawa S, Nanba E (2002) A polymorphism in the serotonin trasporter gene regulatory region and frequency of migraine attacks. Headache 42:893\u2013895","journal-title":"Headache"},{"key":"1010_CR12","doi-asserted-by":"crossref","unstructured":"Park JW, Kim JS, Kim YI, Lee KS Serotoninergic activity contributes to analgesic overuse in chronic ntension-type headache. Headache 45:1229\u20131235","DOI":"10.1111\/j.1526-4610.2005.00247.x"},{"key":"1010_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1526-4610.2008.01257.x","volume":"49","author":"S Cevoli","year":"2009","unstructured":"Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, Cortelli P, Montagna P (2009) Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache 49:412\u2013418","journal-title":"Headache"},{"issue":"9","key":"1010_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1586\/ern.09.80","volume":"9","author":"M Simmaco","year":"2009","unstructured":"Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for predictable disease control. Expert Rev Neurother 9(9):1267\u20131269","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"1010_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1586\/14737175.8.9.1347","volume":"8","author":"I Farinelli","year":"2008","unstructured":"Farinelli I, Missori S, Martelletti P (2008) Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. Expert Rev Neurother 8(9):1347\u20131354","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"1010_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10194-007-0389-4","volume":"8","author":"MB Russell","year":"2007","unstructured":"Russell MB (2007) Genetic in primary headaches. J Headache Pain 8(3):190\u2013195","journal-title":"J Headache Pain"},{"key":"1010_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10194-008-0051-9","volume":"9","author":"FS Mennini","year":"2008","unstructured":"Mennini FS, Gitto S, Martelletti P (2008) Improving care through health economic analyses: cost of illness and headache. J Headache Pain 9:199\u2013206","journal-title":"J Headache Pain"},{"key":"1010_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2146\/ajhp150273","volume":"73","author":"BT Hocum","year":"2016","unstructured":"Hocum BT, White JR Jr, Heck JWE, Thirumaran RK, Moyer N, Newman R, Ashcraft K (2016) Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacognetic testing. Am J Healting Syst Pharm 73:61\u201367","journal-title":"Am J Healting Syst Pharm"},{"key":"1010_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40263-018-0522-8","volume":"32","author":"A Ferrari","year":"2018","unstructured":"Ferrari A, Baraldi C, Licata M, Rustichelli C (2018) Polypharmacy Among Headache Patients: A cross-sectional study. CNS drug 32:567\u2013578","journal-title":"CNS drug"},{"key":"1010_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3390\/ijms19061707","volume":"19","author":"NN Knezevic","year":"2018","unstructured":"Knezevic NN, Tverdohleb T, Knezevic I, Candido KD (2018) The role of genetic polymorphism in chronic pain patients. Int J Mol Sci 19:1707","journal-title":"Int J Mol Sci"},{"key":"1010_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/00498254.2014.894219","volume":"44","author":"N Jinno","year":"2014","unstructured":"Jinno N, Tagashira M, Tsurui K, Yamada S (2014) Contribution of Cytocrome P450 and UDP-glucuronosyltransferase to the metabolism of drug containing carboxylic acid groups: risk assessment of acylglucuronide using human hepatocytes. Xenobiotica 44:677\u2013686","journal-title":"Xenobiotica"},{"key":"1010_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.taap.2005.01.030","volume":"207","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M (2005) The human genome project and novel aspects of Cytocrome P450 research. Toxicol Appl Pharmacol 207:52\u201356","journal-title":"Toxicol Appl Pharmacol"},{"key":"1010_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/tpj.2009.16","volume":"9","author":"P S\u00e0nchez-Diz","year":"2009","unstructured":"S\u00e0nchez-Diz P, Estanyl-Gestal A, Aguirre C, Blanco A, Carracedo A, Ib\u00e0nez L, Passiu M, Provezza L, Ramos-Ruiz R, Ruiz B, Salado-Valdivieso I, Velasco EA, Figueiras A (2009) Prevalence of CYP2C9 polymorphism in the south of Europe. Pharmacogenomics J 9:306\u2013310","journal-title":"Pharmacogenomics J"},{"key":"1010_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/00498254.2010.487163","volume":"40","author":"Y Gao","year":"2010","unstructured":"Gao Y, Liu D, Wang H, Zhu J, Chen C (2010) Funcional characterization of five CYP2C8 variants and prediction of 2C8 genotype dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica 40:467\u2013475","journal-title":"Xenobiotica"},{"key":"1010_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2217\/pgs.09.82","volume":"20","author":"EB Daily","year":"2009","unstructured":"Daily EB, Aquilante CL (2009) Cytochrome P450 2C8 pharmacogenetics: a reviw of clinical studies. Pharmacogenomics 20:1489\u20131510","journal-title":"Pharmacogenomics"},{"key":"1010_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, G\u00f2mez A, Rodr\u00ecguez-Antona C (2007) Influence of Cytochrome P450 polymorphism on drugs therapies: pharmacogenomic, pharmacogenetic and clinical aspects. Pharmacol Ther 116:496\u2013626","journal-title":"Pharmacol Ther"},{"key":"1010_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cld.2007.06.004","volume":"11","author":"GP Aithal","year":"2007","unstructured":"Aithal GP, Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563\u2013575","journal-title":"Clin Liver Dis"},{"key":"1010_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00008571-200308000-00005","volume":"13","author":"J Kirchheiner","year":"2003","unstructured":"Kirchheiner J, Stormer E, Meisel C, Stainbach N, Roots I, Brockmoller J (2003) Influence of CYP2C9 genetic polimorfhisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 13:473\u2013480","journal-title":"Pharmacogenetics"},{"key":"1010_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/00498258609043527","volume":"16","author":"AJ Hutt","year":"1986","unstructured":"Hutt AJ, Caldwell J, Smith RL (1986) The metabolism of aspirin in man: a population study. Xenobiotica 16:239\u2013249","journal-title":"Xenobiotica"},{"key":"1010_CR30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1124\/dmd.105.005652","volume":"34","author":"GE Kuehl","year":"2006","unstructured":"Kuehl GE, Bigler J, Potter JD, Lampe JW (2006) Glucuronidation of the Aspirine metabolite salicylic acid by expressed UDP-glucuronosyltrasferase and human liver microsomes. Drug Metab Dispos 34:100\u2013202","journal-title":"Drug Metab Dispos"},{"key":"1010_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1124\/mol.109.062364","volume":"77","author":"JS Lagas","year":"2010","unstructured":"Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Chinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77:687\u2013694","journal-title":"Mol Pharmacol"},{"key":"1010_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/aiht-2016-67-2754","volume":"67","author":"V Krasniqi","year":"2016","unstructured":"Krasniqi V, Dimovski A, Domajanovic IK, Bilic I, Bozina N (2016) How polymorphism of cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig Rada Toksikol 67:1\u20138","journal-title":"Arh Hig Rada Toksikol"},{"issue":"4","key":"1010_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/sj.clpt.6100159","volume":"82","author":"M Sch\u00fcrks","year":"2007","unstructured":"Sch\u00fcrks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, Rosskopf D (2007) G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther 82(4):396\u2013401","journal-title":"Clin Pharmacol Ther"},{"key":"1010_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10194-010-0241-0","volume":"11","author":"G Gentile","year":"2010","unstructured":"Gentile G, Borro M, Noemi L, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphism related to efficacy and overuse of triptans in chronic migraine. J Headache pain 11:431\u2013435","journal-title":"J Headache pain"},{"issue":"7","key":"1010_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0333102415610874","volume":"36","author":"AF Christensen","year":"2016","unstructured":"Christensen AF, Esserlind AL, Werge T, Stef\u00e1nsson H, Stef\u00e1nsson K, Olesen J (2016) The influence of genetic constitution on migraine drug responses. Cephalalgia. 36(7):624\u2013639","journal-title":"Cephalalgia."},{"key":"1010_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/BF00193709","volume":"47","author":"LF Lacey","year":"1995","unstructured":"Lacey LF, Hussey EK, Flower PA (1995) Single dose pharmacokinetics of Sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543\u2013548","journal-title":"Eur J Clin Pharmacol"},{"key":"1010_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1468-2982.1996.1604270.x","volume":"16","author":"LL Thomsen","year":"1996","unstructured":"Thomsen LL, Dixon R, Lassen LH, Giboens M, Langemark M, Bendtsen L, Daugaard D, Olsen J (1996) C11C90(Zolmitriptan) a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in migraine-free period. Cephalgia 16:270\u2013275","journal-title":"Cephalgia"},{"key":"1010_CR38","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S0009-9236(96)90211-8","volume":"60","author":"L Poulsen","year":"1996","unstructured":"Poulsen L, Arendt-Nielsen L, Brosen K, indrup SH (1996) The Hypoalgesic effect of tramadol in relatation to CYP2D6. Clin Pharmacol Ther 60:636\u2013644","journal-title":"Clin Pharmacol Ther"},{"key":"1010_CR39","first-page":"926","volume":"107","author":"UM Stamer","year":"2007","unstructured":"Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F (2007) Concentraction of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotyper. Clin Pharmacol Ther 107:926\u2013929","journal-title":"Clin Pharmacol Ther"},{"key":"1010_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/JPR.S42040","volume":"6","author":"E Mura","year":"2013","unstructured":"Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH (2013) Consequences of the 118\u00b0>G polymorphism in the OPRM1 gene: transation from bench to beside? J Pain Res 6:331\u2013353","journal-title":"J Pain Res"},{"key":"1010_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1023\/A:1006949816036","volume":"19","author":"MV Rudorfer","year":"1999","unstructured":"Rudorfer MV, Potter WZ (1999) Metabolism of tricyclic antidepressant. Cell Mol Neurobiol 19:373\u2013409","journal-title":"Cell Mol Neurobiol"},{"issue":"5","key":"1010_CR42","first-page":"402","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks JK, Swn JJ, Sangkuhl K, Karasch ED, Elligrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC (2013) Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. CPIC Guidelines 93(5):402\u2013408","journal-title":"CPIC Guidelines"},{"key":"1010_CR43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00007691-198512000-00021","volume":"7","author":"L Bertilsson","year":"1985","unstructured":"Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydrossilation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressant. Ther Drug Monit 7:478\u2013480","journal-title":"Ther Drug Monit"},{"key":"1010_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0140-6736(81)92894-4","volume":"1","author":"L Bertilsson","year":"1981","unstructured":"Bertilsson L, Mellstrom B, Sjokvist F, Martenson B, Asberg M (1981) Slow hydrossilation of nortriptyline and concomitant poor debrisoquine hydrossilation: clinical implication. Lancet 1:560\u2013561","journal-title":"Lancet"},{"key":"1010_CR45","doi-asserted-by":"crossref","unstructured":"Stingl JC, Brokemoller J, Viviani R (2013) Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry.\u00a018(3):273\u201387.","DOI":"10.1038\/mp.2012.42"},{"key":"1010_CR46","first-page":"601","volume":"18","author":"C Palleria","year":"2013","unstructured":"Palleria C, Di Paolo A, Giofr\u00e8 C, Caglioti C, Leuzzi G, Siniscaclchi A, De Sarro G, Gallelli L (2013) Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 18:601\u2013610","journal-title":"J Res Med Sci"},{"key":"1010_CR47","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/STROKEAHA.116.016133","volume":"48","author":"HJA van Os","year":"2017","unstructured":"van Os HJA, Mulder IA, Broesen A, Algra A, van der SChaaf IC, Kappelle LJ, Velthuis BK, Terwindt GM, Schoenville WJ, Viser MC, Ferrari MD, van Wakderveen MAA, Wermwe MJH, DUST investigators (2017) Migraine and cerebrovascular atherosclerosis in patient with ischemic stroke. Stroke 48:1973\u20131975","journal-title":"Stroke"},{"key":"1010_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s10194-017-0718-1","volume":"18","author":"S Seidel","year":"2017","unstructured":"Seidel S, Beisteiner R, Manecke M, Aslan TS, W\u00f6ber C (2017) Psychiatric comorbidities and photophobia in patient with migraine. J Headache Pain 18:18","journal-title":"J Headache Pain"},{"key":"1010_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-017-0764-8","volume":"18","author":"M de Tommaso","year":"2017","unstructured":"de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M, Barbaro MGF (2017) Symptoms of central sensitization and comorbidity for juvenile fibromyalgia in childhood migraine; an observational study in a tert6iary center. J Headache Pain 18:59","journal-title":"J Headache Pain"},{"key":"1010_CR50","first-page":"559","volume":"32","author":"LM Pomes","year":"2018","unstructured":"Pomes LM, Gentile G, Borro M, Simmaco M, Martelletti P (2018) Tailoring Treatement in Polymorbid Migraine Patients trought Personalized Medicine.CNS drug- springer. Nature 32:559\u2013565","journal-title":"Nature"},{"key":"1010_CR51","volume-title":"Relase of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","author":"PJ Goadsby","year":"1988","unstructured":"Goadsby PJ, Edvisson L, Ekmark R (1988) Relase of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system"},{"key":"1010_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10194-008-0011-4","volume":"9","author":"AS Link","year":"2008","unstructured":"Link AS, Kuris A, Edvinsson L (2008) Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 9:5\u201312","journal-title":"J Headache Pain"},{"key":"1010_CR53","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-releted peptide receptor antagonist BIBn4096 BS for acute treatment of migraine. N Engl J Med 350:1104\u20131110","journal-title":"N Engl J Med"},{"key":"1010_CR54","doi-asserted-by":"publisher","first-page":"14294","DOI":"10.1074\/jbc.M109661200","volume":"277","author":"JJ Mallee","year":"2002","unstructured":"Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS et al (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 277:14294\u201314298","journal-title":"J Biol Chem"},{"key":"1010_CR55","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pjnns.2016.07.012","volume":"50","author":"O Kuzawi\u0144ska","year":"2016","unstructured":"Kuzawi\u0144ska O, Lis K, Cessak G, Mirowska-guzel D, Balkowiec-Iskra E (2016) Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment. Neurol I Neurochir Polska Rev Art 50:463\u2013467","journal-title":"Neurol I Neurochir Polska Rev Art"},{"key":"1010_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0306-3623(95)00125-5","volume":"27","author":"SD Brain","year":"1996","unstructured":"Brain SD, Cambridge H (1996) Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen Pharmacol 27:607\u2013611","journal-title":"Gen Pharmacol"},{"key":"1010_CR57","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s13311-018-0617-4","volume":"15","author":"PR Holland","year":"2018","unstructured":"Holland PR, Goadsby PJ (2018) Targetd CGRP small molecule antagonist for acute migraine therapy. Neurotherapeutics 15:304\u2013312","journal-title":"Neurotherapeutics"},{"key":"1010_CR58","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.2147\/JPR.S152216","volume":"11","author":"JC Oswald","year":"2018","unstructured":"Oswald JC, Schuster NM (2018) Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J of Pain Research 11:2221\u20132227","journal-title":"J of Pain Research"},{"key":"1010_CR59","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB (2018) COL MIG-301 Study Group; Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 91(24):e2222\u2013e2232"},{"key":"1010_CR60","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1212\/01.wnl.0000427909.23467.39","volume":"80","author":"PC Tfelt-Hansen","year":"2013","unstructured":"Tfelt-Hansen PC (2013) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American headache society. Neurology 80:869\u2013870","journal-title":"Neurology"},{"key":"1010_CR61","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fphar.2017.00740","volume":"8","author":"D Monteith","year":"2017","unstructured":"Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, Grayzel D, Schuetz TJ, de Hoon J (2017) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers. Front Pharmacol 8:740","journal-title":"Front Pharmacol"},{"issue":"5","key":"1010_CR62","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/head.12559","volume":"55","author":"S Cargnin","year":"2015","unstructured":"Cargnin S, Pautasso C, Viana M, Sances G, Mittino D, Cantello R, Tassorelli C, Nappi G, Terrazzino S (2015) Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache. Headache. 55(5):658\u2013668","journal-title":"Headache."},{"issue":"1","key":"1010_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.gene.2012.11.053","volume":"515","author":"HG Sutherland","year":"2013","unstructured":"Sutherland HG, Buteri J, Menon S, Haupt LM, Macgregor EA, Lea RA, Griffiths LR (2013) Association study of the calcitonin gene-related polypeptide-alpha (CALCA) and the receptor activity modifying 1 (RAMP1) genes with migraine. Gene. 515(1):187\u2013192","journal-title":"Gene."},{"issue":"5","key":"1010_CR64","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.113.02517","volume":"63","author":"SJ Smillie","year":"2014","unstructured":"Smillie SJ, King R, Kodji X, Outzen E, Pozgai G, Fernandes E et al (2014) An ongoing role of \u03b1- calcitonin gene- related peptide as part of a protective network aginst hypertention, vascular hypertrophy, and oxidative stress. Hypertention 63(5):1056\u20131062","journal-title":"Hypertention"},{"issue":"6","key":"1010_CR65","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpdd.345","volume":"6","author":"L Pellesi","year":"2017","unstructured":"Pellesi L, Guerzoni S, Pini LA (2017) Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev 6(6):534\u2013547","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1010_CR66","doi-asserted-by":"publisher","unstructured":"Lambru G, Andreou AP, Guglielmetti M,\u00a0Martelletti\u00a0P (2018)\u00a0Emerging drugs for migraine treatment: an update.\u00a0Expert Opin Emerg Drugs. \n                    https:\/\/doi.org\/10.1080\/14728214.2018.1552939","DOI":"10.1080\/14728214.2018.1552939"},{"issue":"35","key":"1010_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10072-014-1747-z","volume":"1","author":"S Vollbracht","year":"2014","unstructured":"Vollbracht S, Rapoport AM (2014) New treatments for headache. Neurol Sci 1(35):89\u201397","journal-title":"Neurol Sci"},{"key":"1010_CR68","doi-asserted-by":"crossref","unstructured":"Lionetto L, Cipolla F, Guglielmetti M,\u00a0Martelletti\u00a0P (2019)\u00a0Fremanezumab for the prevention of chronic and episodic migraine.\u00a0Drugs Today 55(4):265\u2013276","DOI":"10.1358\/dot.2019.55.4.2970909"},{"issue":"11","key":"1010_CR69","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100\u20131107","journal-title":"Lancet Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-019-1010-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T23:17:36Z","timestamp":1589584656000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-019-1010-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1186\/s10194-019-1010-3","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"56"}}